Login / Signup

Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort.

Antonino PantaleoGiovanna ForteFilomena CariolaAnna Maria ValentiniCandida FasanoPaola SaneseValentina GrossiAntonia Lucia BuonadonnaKatia De MarcoMartina Lepore SignorileAnna Filomena GuglielmiAndrea ManghisiGianluigi GiganteRaffaele ArmentanoVittoria DisciglioCristiano Simone
Published in: Cancers (2023)
Lynch syndrome (LS) is an inherited cancer susceptibility syndrome caused by germline mutations in a DNA mismatch repair (MMR) gene or in the EPCAM gene. LS is associated with an increased lifetime risk of colorectal cancer (CRC) and other malignancies. The screening algorithm for LS patient selection is based on the identification of CRC specimens that have MMR loss/high microsatellite instability (MSI-H) and are wild-type for BRAF V600 . Here, we sought to clinically and molecularly characterize patients with these features. From 2017 to 2023, 841 CRC patients were evaluated for MSI and BRAF V600E mutation status, 100 of which showed MSI-H. Of these, 70 were wild-type for BRAF V600 . Among these 70 patients, 30 were genetically tested for germline variants in hereditary cancer predisposition syndrome genes. This analysis showed that 19 of these 30 patients (63.3%) harbored a germline pathogenic or likely pathogenic variant in MMR genes, 2 (6.7%) harbored a variant of unknown significance (VUS) in MMR genes, 3 (10%) harbored a VUS in other cancer-related genes, and 6 (20%) were negative to genetic testing. These findings highlight the importance of personalized medicine for tailored genetic counseling, management, and surveillance of families with LS and other hereditary cancer syndromes.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • wild type
  • genome wide
  • peritoneal dialysis
  • papillary thyroid
  • prognostic factors
  • copy number
  • genome wide identification
  • transcription factor
  • genetic diversity